Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB-401 in atopic dermatitis
NCT04504279Phase 2Completed
- Sponsor
- Forte Biosciences, Inc.
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing FB-401 with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving at least a 50% improvement in Eczema Area and Severity Index at 16 weeks. Started Oct 2020; status: completed.
02
Drugs
FB-401
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04504279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504279.